ArticleBMC infectious diseases2025
Detection of AcrAB efflux pump mediated ciprofloxacin resistance in Escherichia coli and Klebsiella pneumoniae in Nepal.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- MappingAntibiotics (Basel, Switzerland) · 2026Article
- Comprehensive genotypic report of carbapenem-resistant Klebsiella pneumoniae (CRKP) harboring carbapenemase-resistant genes, porin loss and efflux pump genes in Osun State, Nigeria.Molecular biology reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntimicrobial resistance (AMR) has emerged as a serious public health threat with a sharply increasing burden globally. Resource limited countries like Nepal are facing difficulties in the fight against AMR. This has been further worsened due to the lack of adequate molecular data. Ciprofloxacin resistance by AcrAB-TolC efflux pump (EP) genes in Gram-negative bacteria becomes a challenging issue due to its potential role in multidrug resistance (MDR). This hospital-based cross-sectional study investigated these genes in ciprofloxacin-resistant Escherichia coli and Klebsiella pneumoniae isolates from patients attending a tertiary care hospital in Kathmandu, Nepal. Different clinical specimens (n = 877) were subjected to bacterial isolation and identification. Antibiotic susceptibility testing was performed by Kirby-Bauer disc diffusion technique and minimum inhibitory concentration (MIC) by agar dilution. AcrAB-TolC genes were detected by polymerase chain reaction (PCR).
resultsOut of 877 samples, 124 (14.1%) showed bacterial growth, comprising 59 (47.6%) E. coli, 39 (31.4%) K. pneumoniae, and 26 (20.9%) other bacterial species. MDR was observed in 66.1% of E. coli and 89.7% of K. pneumoniae. Ciprofloxacin resistance was seen in 57.6% of E. coli and 71.8% of K. pneumoniae isolates. Majority of E. coli (10) and K. pneumoniae (8) isolates showed MIC of ciprofloxacin as 256 µg/mL and 512 µg/mL, respectively. There was significant association between ciprofloxacin resistance and MDR (p < 0.05). The higher proportion of AcrAB-TolC genes was detected in ciprofloxacin-resistant MDR isolates of E. coli (87.5%) and K. pneumoniae (66.7%) compared to non-MDR isolates.
conclusionsClinical isolates of E. coli and K. pneumoniae exhibited alarmingly high MDR rates with substantial resistance to commonly prescribed antibiotics in Nepal. We also observed a notable presence of EP-mediated resistance in these isolates. These findings highlight the urgent need for enhanced AMR surveillance (including resistance marker screening and genomic surveillance) and development of evidence-based antibiotic stewardship programs to address the growing burden of MDR Nepal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.